Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Operating Income: 2019-2024

Historic Operating Income for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$119.6 million.

  • C4 Therapeutics' Operating Income fell 21.84% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 8.76%. This contributed to the annual value of -$119.6 million for FY2024, which is 13.97% up from last year.
  • Latest data reveals that C4 Therapeutics reported Operating Income of -$119.6 million as of FY2024, which was up 13.97% from -$139.0 million recorded in FY2023.
  • C4 Therapeutics' Operating Income's 5-year high stood at -$60.4 million during FY2020, with a 5-year trough of -$139.0 million in FY2023.
  • In the last 3 years, C4 Therapeutics' Operating Income had a median value of -$129.5 million in 2022 and averaged -$129.4 million.
  • Per our database at Business Quant, C4 Therapeutics' Operating Income plummeted by 70.51% in 2020 and then grew by 13.97% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Operating Income stood at -$60.4 million in 2020, then plummeted by 35.87% to -$82.1 million in 2021, then slumped by 57.71% to -$129.5 million in 2022, then decreased by 7.33% to -$139.0 million in 2023, then grew by 13.97% to -$119.6 million in 2024.